Pediatric Praziquantel Consortium

Taking the next step towards access with continued support from the GHIT Fund

09 May 2019

The fourth research grant from the Global Health Innovative Technology (GHIT) Fund provides further support for the...

World Health Day: Working towards universal health coverage in Africa

03 April 2019

The Pediatric Praziquantel Consortium marks the World Health Day through its continuous effort to register and...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more